TRUMPF Venture participates in Series D in the amount of 13 million euros at iThera Medical
Stuttgart — TRUMPF Venture II GmbH (“TRUMPF Venture”) made an investment of 13 million euros in the Series D financing round of Munich-based medtech company iThera Medical GmbH (“iThera Medical”). TRUMPF Venture received legal and tax advice on this transaction from Heuking Partner in Stuttgart. In addition to TRUMPF Venture, existing investors such as Bayern Kapital again participated with money from the Bavarian Growth Fund. Further investments were made by the European Council Fund of the EU Commission, Mey Capital Matrix and Fluxunit. The company intends to use the capital to develop its own diagnostic product to market maturity and to obtain regulatory approval in Europe and the USA.
TRUMPF Venture is a strategic as well as corporate venture capital investor specializing in the promotion of promising start-ups in the industry worldwide. TRUMPF Venture positions itself as a long-term development partner. TRUMPF Venture usually seeks minority stakes of between five and 25 percent.
iThera Medical is a start-up for optoacoustic imaging in medical diagnostics. A new development of the company is the so-called MSOT technology (Multispectral Optoacoustic Tomography). Through this technology, disease patterns such as cancer or fibrosis can be diagnosed. By converting light energy into sound waves, different types of tissue in the body can thus be characterized, differentiated and displayed in 3D images.
iThera Medical was founded in 2010 as a spin-off of Helmholtz Zentrum München.
Advisors to Trumpf Venture GmbH: Heuking Kühn Lüer Wojtek
Dr. Hermann Ali Hinderer, LL.M. (lead), Anika Lisa Daschmann (both Private Equity / Venture Capital), Antje Münch, LL.M. (IP), all Stuttgart;
Laura-Felicia Bokranz, LL.M. (University of Cape Town), Christoph Hexel (both Labor Law), both Düsseldorf; Cécile Corbet, LL.M. (Patent Law), Frankfurt;
Dr. Martin Schellenberg (Public Law), Dr. Sarah Slavik-Schulz (Tax Law), both Hamburg